Clinical Trials in Rocky Mount, North Carolina
11 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled759 locationsNCT06742723
Recruiting
Phase 2
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Hypertension
Novartis Pharmaceuticals380 enrolled84 locationsNCT06857955
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled928 locationsNCT06677060
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Breast Cancer
Exact Sciences Corporation1,800 enrolled58 locationsNCT06401421
Recruiting
Phase 3
Vitamin D for Prostate Endocrine Therapy
Stage III Prostate Cancer AJCC v8Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8+1 more
University of Rochester240 enrolled51 locationsNCT05838716
Recruiting
Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acute Coronary Syndrome
DalCor Pharmaceuticals2,000 enrolled223 locationsNCT05918861
Recruiting
Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
COVID-19
BioNTech SE25,500 enrolled208 locationsNCT07300839
Recruiting
Not Applicable
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers
Lower ExtremityDiabetic Foot Ulcer (DFU)
LifeNet Health120 enrolled18 locationsNCT07116876
Recruiting
Phase 4
Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC)
Diabetic Foot Ulcer
Cellution Biologics120 enrolled8 locationsNCT07014176